Table 2 Number of patients with treatment-related adverse events

From: Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial

 

Pembrolizumab (N = 28)

Any grade

Grade 3

Any AE

22 (79%)

2 (7%)

Any SAE

0 (0%)

0 (0%)

AE/toxicity led to discontinuation of treatment

1 (4%)

—

Immune-related AEa

12 (43%)

1 (4%)

 SAE

0 (0%)

0 (0%)

 AE led to death

0 (0%)

0 (0%)

  1. All adverse events reported were assessed as possibly, probably or definitely related to the study treatment. To be included in the safety analysis, patients must have received at least one dose of protocol therapy. Adverse event severity was scored using the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. There were no grade 4 or 5 (led to death) adverse events reported.
  2. aThere was one incidence of grade 3 oral mucositis that was reported as a late effect and is unknown if deemed to be immune related.
  3. AE, adverse event; SAE, serious adverse event.
Back to article page